Related Experiment Video
Updated: Jun 27, 2026

Visualizing Antigen Specific CD4+ T Cells using MHC Class II Tetramers
Published on: March 6, 2009
Using major histocompatibility complex (MHC) II expression to predict antitumor response to CD4 + lymphocyte
Yanping Wang1, Minhyung Kim1, Shengchen Su1
1Department of Urology, Cedars Sinai Medical Center, 8635 W. Third St, 1070, Los Angeles, CA, 90048, USA.
Abstract:
Immunotherapy targeting CD4 + FoxP3 + regulatory T cells (Tregs) through CD4 + lymphocyte depletion is being investigated as cancer treatment. This study examines the efficacy and limitations of CD4 depletion across various cancer models. We examined CD4 depletion in syngeneic mouse tumor models including B16 melanoma, Renca kidney cancer, and Hepa1-6 hepatocellular carcinoma. The study explored the relationship between MHC II expression and tumor growth, immune response, and survival. In mouse models, CD4 depletion suppressed B16 and Renca tumor growth but accelerated Hepa1-6 tumors. Hepa1-6 had high MHC II expression while the other two lines had low MHC II expression. Manipulation of MHC II expression in Hepa1-6 and Renca cell lines confirmed the mechanistic importance of MHC II in generating a CD4-based antitumor immune response. Analysis of the TCGA dataset supports the relevance of this mechanism in patients. In tumors with high MHC II and low MHC I expression, increased CD4 levels correlated with improved survival. CD4 depletion can suppress tumor growth or promote tumor growth, depending on tumor MHC expression status. MHC status may identify tumors where intratumor CD4 may be a better early-response marker than CD8.
Insights
Cancer immunotherapy using CD4+ T cell depletion shows varied results. Tumor MHC II expression dictates whether CD4+ T cell depletion suppresses or enhances tumor growth, impacting patient survival and treatment strategies.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Immunotherapy targeting CD4+FoxP3+ regulatory T cells (Tregs) via CD4+ lymphocyte depletion is a developing cancer treatment strategy.
- Understanding the efficacy and limitations of CD4 depletion across diverse cancer types is crucial.
Purpose of the Study:
- To investigate the efficacy and limitations of CD4 depletion in various syngeneic mouse tumor models.
- To explore the relationship between MHC II expression, tumor growth, immune response, and survival.
- To validate findings in human cancer data.
Main Methods:
- CD4 depletion was examined in B16 melanoma, Renca kidney cancer, and Hepa1-6 hepatocellular carcinoma mouse models.
- MHC II expression's role was investigated by manipulating MHC II levels in cancer cell lines.
- TCGA dataset analysis was performed to assess clinical relevance.
Main Results:
- CD4 depletion suppressed B16 and Renca tumor growth but accelerated Hepa1-6 tumor growth.
- Hepa1-6 tumors exhibited high MHC II expression, while B16 and Renca showed low MHC II expression.
- TCGA data indicated that high MHC II/low MHC I tumors with increased CD4 levels correlated with improved survival.
Conclusions:
- CD4 depletion's effect on tumor growth is contingent on tumor MHC II expression status.
- MHC status may determine if intratumor CD4 levels are a more effective early-response marker than CD8.
- This highlights the potential for personalized cancer immunotherapy based on MHC expression.
More Related Videos
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
12:09Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
Related Concept Videos
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...